| Title |
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, January 2016
|
| DOI | 10.1007/s10549-016-3685-3 |
| Pubmed ID | |
| Authors |
Joanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, Pal Moller, Henry T. Lynch, Susan L. Neuhausen, Leigha Senter, Rochelle Demsky, William D. Foulkes, Charis Eng, Beth Karlan, Nadine Tung, Christian F. Singer, Ping Sun, Jan Lubinski, Steven A. Narod |
| Abstract |
Many BRCA1 mutation carriers undergo elective surgical oophorectomy (often before menopause) to manage their elevated risk of developing ovarian cancer. It is important to clarify whether or not the use of hormone replacement therapy (HRT) to mitigate the symptoms associated with surgical or natural menopause is safe in women with an inherited BRCA1 mutation and no personal history of breast or ovarian cancer. We conducted a case-control analysis of 432 matched pairs of women with a BRCA1 mutation. Detailed information on HRT use after menopause (duration, type, age at first/last use, formulation) was obtained from a research questionnaire administered at the time of study enrollment. Conditional logistic regression was used to estimate the odds ratio (OR) and 95 % confidence intervals (CI) associated with HRT use. The mean duration of HRT use after menopause was 4.3 years among the cases and 4.4 years among the controls (P = 0.83). The adjusted OR for breast cancer comparing all women who ever used HRT to those who never used HRT was 0.80 (95 % CI 0.55-1.16; P = 0.24). Findings did not differ by type of menopause (natural vs. surgical), by recency of use, by duration of use, and by formulation type. These findings suggest that a short course of HRT should not be contra-indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 38% |
| Switzerland | 1 | 8% |
| Unknown | 7 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | 1% |
| Unknown | 70 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 13% |
| Researcher | 9 | 13% |
| Student > Bachelor | 6 | 8% |
| Other | 6 | 8% |
| Student > Doctoral Student | 5 | 7% |
| Other | 16 | 23% |
| Unknown | 20 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 38% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Nursing and Health Professions | 4 | 6% |
| Unspecified | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 6 | 8% |
| Unknown | 25 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2016.
All research outputs
#3,102,469
of 22,840,638 outputs
Outputs from Breast Cancer Research and Treatment
#500
of 4,660 outputs
Outputs of similar age
#56,838
of 392,526 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#5
of 64 outputs
Altmetric has tracked 22,840,638 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,660 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 392,526 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.